ITCI
ITCI Real Time Price USDRecent trades of ITCI by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ITCI holdings by institutional investors
Quarterly net insider trading by ITCI's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$50,000 Oct 16, 2025 Issue: Health Issues
-
$10,000 Jul 21, 2025 Issue: Medicare/Medicaid
-
$70,000 Apr 21, 2025 Issue: Medicare/Medicaid Taxation/Internal Revenue Code
-
$40,000 Jan 17, 2025 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$50,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$50,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$70,000 Apr 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$40,000 Jan 22, 2024 Issue: Health Issues
-
$10,000 Oct 19, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$40,000 Jul 17, 2023 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
-
$50,000 Jan 19, 2023 Issue: Health Issues Medicare/Medicaid
-
$15,000 Nov 21, 2022 Issue: Medicare/Medicaid Health Issues
-
$20,000 Oct 20, 2022 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
-
$10,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
-
$20,000 Feb 28, 2005 Issue: Budget/Appropriations
-
$20,000 Aug 20, 2004 Issue: Budget/Appropriations
ITCI Estimated quarterly lobbying spending
ITCI Revenue by Segment or Geography
New ITCI patent grants
-
Patent Title: Methods and compositions for sleep disorders and other disorders Dec. 07, 2021
-
Patent Title: 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms Nov. 23, 2021
-
Patent Title: Method for the treatment of residual symptoms of schizophrenia May. 01, 2018
-
Patent Title: Organic compounds Apr. 17, 2018
-
Patent Title: Organic compounds Apr. 10, 2018
-
Patent Title: Organic compounds Feb. 06, 2018
-
Patent Title: Products and pharmaceutical compositions Dec. 26, 2017
-
Patent Title: Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases Oct. 31, 2017
-
Patent Title: Pde1 inhibitory compounds and methods Sep. 19, 2017
-
Patent Title: Preparation of certain [((6br,10as)-2,3,6b,7,8,9,10, 10a-octahydro-1h-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof Sep. 05, 2017
-
Patent Title: Organic compounds Aug. 29, 2017
-
Patent Title: Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity Jul. 18, 2017
-
Patent Title: Organic compounds Jul. 18, 2017
-
Patent Title: Free base crystals Apr. 25, 2017
-
Patent Title: Organic compounds Apr. 18, 2017
-
Patent Title: Methods and compositions for sleep disorders and other disorders Apr. 11, 2017
-
Patent Title: Regulatory proteins and inhibitors Mar. 28, 2017
-
Patent Title: Organic compounds Mar. 21, 2017
-
Patent Title: 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7h)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms Mar. 07, 2017
-
Patent Title: Organic compounds Jan. 31, 2017
-
Patent Title: Organic compounds Jan. 31, 2017
-
Patent Title: Organic compounds Jan. 17, 2017
-
Patent Title: Method of treating a cns injury with a pde1 inhibitor Jan. 17, 2017
-
Patent Title: Pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-dione derivatives useful as inhibitors of phosphodiesterase i Nov. 08, 2016
-
Patent Title: Salt crystals Oct. 18, 2016
-
Patent Title: Organic compounds Oct. 18, 2016
-
Patent Title: Organic compounds Oct. 18, 2016
-
Patent Title: Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists Sep. 27, 2016
-
Patent Title: Pde1 inhibitor compounds Sep. 06, 2016
-
Patent Title: Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders Aug. 30, 2016
-
Patent Title: Organic compounds Aug. 02, 2016
-
Patent Title: Pde1 inhibitor compounds Jun. 21, 2016
-
Patent Title: Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders Jun. 21, 2016
-
Patent Title: Methods of treating vasomotor symptoms May. 17, 2016
-
Patent Title: Preparation of 4-((6br,10as)-3-methyl-2,3,6b,9,10, 10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7h)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof Apr. 19, 2016
-
Patent Title: Pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-diones as phosphodiesterase 1 inhibitors Feb. 09, 2016
-
Patent Title: 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7h)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals Dec. 01, 2015
-
Patent Title: Organic compounds Dec. 01, 2015
-
Patent Title: Methods and compositions for sleep disorders and other disorders Oct. 27, 2015
-
Patent Title: Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists Aug. 18, 2015
-
Patent Title: Organic compounds Jul. 07, 2015
-
Patent Title: Heterocycle compounds and uses thereof Jun. 23, 2015
-
Patent Title: Heterocycle compounds and uses thereof Jun. 16, 2015
-
Patent Title: Method of treating female sexual dysfunction with a pde1 inhibitor Apr. 14, 2015
-
Patent Title: Organic compounds Apr. 07, 2015
-
Patent Title: Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives Mar. 31, 2015
-
Patent Title: 1h-pyrrolo[3,4-d]pyrimidin-2(6h)-one compounds Jan. 06, 2015
-
Patent Title: Pyrazolo[3,4-d]pyrimidine-4,6(5h,7h)-dione derivatives useful as inhibitors of phosphodiesterase 1 Oct. 14, 2014
-
Patent Title: Phosphodiesterase 1-targeting tracers and methods Oct. 14, 2014
-
Patent Title: Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones Sep. 30, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ITCI from public contracts
Recent insights relating to ITCI
Recent picks made for ITCI stock on CNBC
ETFs with the largest estimated holdings in ITCI
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ITCI stock a Buy, Sell, or Hold?
- What is the price target for $ITCI stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ITCI stock?
- Who owns the most shares of $ITCI stock?
- What funds own $ITCI stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ITCI Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
No description available